- 2024.07.22
A powerful tool is added again for the treatment of Alzheimer’s disease! The IMC of Heyou Zhizhen Hospital welcomes the first batch of Lecanemab in Guangdong Province.
Lecanemab is the first targeted new drug for Alzheimer’s disease (abbreviated as AD) fully approved by the US Food and Drug Administration (FDA) in 20 years, and it has been completed with priority review and approval in China. The IMC of Heyou Zhizhen Hospital is the first batch of hospitals in Guangdong Province to introduce the new drug “Lecanemab”. It has been completed with distribution recently and can be put into clinical use.